The FDA granted accelerated approval to pemigatinib (Pemazyre, Incyte ), the first approved treatment for adults with previously treated cholangiocarcinoma that is locally advanced or metastatic and has a fusion or other rearrangement in FGFR2.
“With Pemazyre, we considered the observed efficacy results to be clinically meaningful and the overall risk-to-benefit assessment for patients with tumors harboring FGFR2 [fibroblast growth factor receptor 2] gene fusions and otherAPRIL 21, 2020